代谢相关脂肪性肝病的流行病学现状及诊治研究进展
Research advances in epidemiological situation and diagnosis and treatment of metabolism-associated fatty liver disease
- 解放军医学杂志 2023年48卷第12期 页码：1457-1466
- 作者机构：
1.解放军总医院第二医学中心消化内科/国家老年疾病临床医学研究中心，北京 100853
2.解放军医学院，北京 100853
- 作者简介：
庄颖洁，医学硕士，主要从事慢性肝病等方面的临床研究
高利利，E-mail： gll301818@163.com
- 基金信息：国家自然科学基金面上项目(81570563)
DOI：10.11855/j.issn.0577-7402.0545.2023.0807
中图分类号：
扫 描 看 全 文
庄颖洁, 刘文徽, 刘正一, 等. 代谢相关脂肪性肝病的流行病学现状及诊治研究进展[J]. 解放军医学杂志, 2023, 48(12): 1457-1466.
Zhuang Ying-Jie,Liu Wen-Hui,Liu Zheng-Yi,et al.Research advances in epidemiological situation and diagnosis and treatment of metabolism-associated fatty liver disease[J].Medical Journal of Chinese People′s Liberation Army,2023,48(12):1457-1466.
庄颖洁, 刘文徽, 刘正一, 等. 代谢相关脂肪性肝病的流行病学现状及诊治研究进展[J]. 解放军医学杂志, 2023, 48(12): 1457-1466. DOI： 10.11855/j.issn.0577-7402.0545.2023.0807.
Zhuang Ying-Jie,Liu Wen-Hui,Liu Zheng-Yi,et al.Research advances in epidemiological situation and diagnosis and treatment of metabolism-associated fatty liver disease[J].Medical Journal of Chinese People′s Liberation Army,2023,48(12):1457-1466. DOI： 10.11855/j.issn.0577-7402.0545.2023.0807.
摘要
代谢相关脂肪性肝病(MAFLD)曾用名非酒精性脂肪性肝病(NAFLD)，是全球最流行的慢性肝脏疾病之一，已经成为肝硬化、终末期肝病及原发性肝癌的主要原因之一。近年来MAFLD患病率在中国及亚太地区，甚至全球逐渐增高，加重了医疗及社会经济负担，国内外对该病的流行病学及危险因素的探索也逐渐增多。同时，由于MAFLD治疗药物少，其药物治疗也成为临床亟待解决的热点问题，近年进入临床试验阶段的药物明显增多。基于此，本文针对当前MAFLD的流行病学现状、危险因素、诊断标准及治疗研究进展进行综述，以期为MAFLD的临床诊疗及科研提供新的思路与方向。
Abstract
Metabolism-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is one of the most popular chronic liver diseases in the world, and has become one of the main causes of liver cirrhosis, end-stage liver disease, and primary liver cancer. In recent years, the prevalence of MAFLD has gradually increased in China, the Asia Pacific region, and even globally, increasing the medical and socio-economic burden. The exploration of the epidemiology and risk factors of this disease at home and abroad has also gradually increased. Meanwhile, due to the scarcity of MAFLD treatment drugs, their drug treatment has become a hot issue that needs to be urgently addressed in clinical practice. In recent years, there has been an increase in the number of drugs entering the clinical trial stage. Based on this, the current epidemiological status, risk factors, diagnostic criteria, and treatment research progress of MAFLD have been reviewed in order to provide new ideas and directions for the clinical diagnosis, treatment, and scientific research of MAFLD.
关键词
非酒精性脂肪性肝病流行病学危险因素诊断治疗学
Keywords
non-alcoholic fatty liver diseaseepidemiologyrisk factorsdiagnosistherapeutics
references
Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1.
Eslam M, Sarin SK, Wong VWS, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020, 14(6): 889-919.
Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224.
Tateishi R, Uchino K, Fujiwara N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update[J]. J Gastroenterol, 2019, 54(4): 367-376.
Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates[J]. Clin Gastroenterol Hepatol, 2019, 17(4): 748-755.e3.
Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China[J]. J Hepatol, 2005, 43(3): 508-514.
Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China[J]. World J Gastroenterol, 2007, 13(47): 6419-6424.
Li H, Wang YJ, Tan K, et al. Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China[J]. Hepatobiliary Pancreat Dis Int, 2009, 8(4): 377-382.
Li HB, Guo MH, An Z, et al. Prevalence and risk factors of metabolic associated fatty liver disease in Xinxiang, China[J]. Int J Environ Res Public Health, 2020, 17(6): 1818.
Li J, Zou BY, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398.
Zhou F, Zhou JH, Wang WX, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133.
Chan KE, Koh TJL, Tang ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals[J]. J Clin Endocrinol Metab, 2022, 107(9): 2691-2700.
Lin HP, Zhang XR, Li GL, et al. Epidemiology and clinical outcomes of metabolic (dysfunction)-associated fatty liver disease[J]. J Clin Transl Hepatol, 2021, 9(6): 972-982.
Lin S, Huang JF, Wang MF, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world[J]. Liver Int, 2020, 40(9): 2082-2089.
Wong VWS, Wong GLH, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease[J]. Clin Gastroenterol Hepatol, 2021, 19(10): 2161-2171.e5.
Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases[J]. Int J Mol Sci, 2021, 22(21): 11629.
Miyake T, Kumagi T, Hirooka M, et al. Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study[J]. J Gastroenterol, 2013, 48(3): 413-422.
Cuzmar V, Alberti G, Uauy R, et al. Early obesity: risk factor for fatty liver disease[J]. J Pediatr Gastroenterol Nutr, 2020, 70(1): 93-98.
Liu HL, Gong WH. Research on the elderly body mass index change effect on the pathogenesis of nonalcoholic fatty liver disease[J]. Chin Primary Health Care, 2020, 34(9): 72-74.
刘怀磊, 龚卫红. 老年人BMI变化对非酒精性脂肪性肝病发病的影响研究[J]. 中国初级卫生保健, 2020, 34(9): 72-74.
Nishioji K, Sumida Y, Kamaguchi M, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012[J]. J Gastroenterol, 2015, 50(1): 95-108.
Chen WJ, Ayiguli YS, Cheng RR, et al. Gong WH. Phenotypic characteristics and cardiovascular risk factors of non-obese patients with NAFLD[J]. J Xinjiang Med Univ, 2020, 43(6): 808-814.
陈文婧, 阿依古丽·玉素甫, 程蕊蕊, 等. 非肥胖非酒精性脂肪肝病患者心血管疾病危险因素分析[J]. 新疆医科大学学报, 2020, 43(6): 808-814.
Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2017, 23(47): 8263-8276.
Demirtas CO, Sapmaz A, Gurel BA, et al. The clinical and histological characteristics of patients with biopsy-proven non-alcoholic fatty liver disease in the absence of insulin resistance[J]. Hepatol Forum, 2020, 1(3): 101-108.
Eslam M, Chen F, George J. NAFLD in lean asians[J]. Clin Liver Dis (Hoboken), 2021, 16(6): 240-243.
Mantovani A, Byrne CD, Bonora E, et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis[J]. Diabetes Care, 2018, 41(2): 372-382.
Hedayatnia M, Asadi Z, Zare-Feyzabadi R, et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population[J]. Lipids Health Dis, 2020, 19(1): 42.
Wu SA, Kersten S, Qi L. Lipoprotein lipase and its regulators: an unfolding story[J]. Trends Endocrinol Metab, 2021, 32(1): 48-61.
Mucinski JM, Manrique-Acevedo C, Kasumov T, et al. Relationships between very low-density lipoproteins-ceramides, -diacylglycerols, and-triacylglycerols in insulin-resistant men[J]. Lipids, 2020, 55(4): 387-393.
Li SW, Fu YH, Liu Y, et al. Serum uric acid levels and nonalcoholic fatty liver disease: a 2-sample bidirectional Mendelian randomization study[J]. J Clin Endocrinol Metab, 2022, 107(8): e3497-e3503.
Fava F, Gitau R, Griffin BA, et al. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome 'at-risk' population[J]. Int J Obes (Lond), 2013, 37(2): 216-223.
Semmler G, Datz C, Reiberger T, et al. Diet and exercise in NAFLD/NASH: beyond the obvious[J]. Liver Int, 2021, 41(10): 2249-2268.
Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss[J]. BMC Endocr Disord, 2022, 22(1): 63.
Stefano JT, Duarte SMB, Ribeiro Leite Altikes RG, et al. Non-pharmacological management options for MAFLD: a practical guide[J]. Ther Adv Endocrinol Metab, 2023, 14: 20420188231160394.
Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577.
Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)[J]. Cell Mol Life Sci, 2019, 76(8): 1541-1558.
Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease[J]. Nat Rev Nephrol, 2017, 13(5): 297-310.
Sun DQ, Jin Y, Wang TY, et al. MAFLD and risk of CKD[J]. Metabolism, 2021, 115: 154433.
Colognesi M, Gabbia D, de Martin S. Depression and cognitive impairment-extrahepatic manifestations of NAFLD and NASH[J]. Biomedicines, 2020, 8(7): 229.
Youssef NA, Abdelmalek MF, Binks M, et al. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease[J]. Liver Int, 2013, 33(7): 1062-1070.
Celikbilek A, Celikbilek M, Bozkurt G. Cognitive assessment of patients with nonalcoholic fatty liver disease[J]. Eur J Gastroenterol Hepatol, 2018, 30(8): 944-950.
Demir S, Nawroth PP, Herzig S, et al. Emerging targets in type 2 diabetes and diabetic complications[J]. Adv Sci, 2021, 8(18): e2100275.
Spremović Rađenović S, Pupovac M, Andjić M, et al. Prevalence, risk factors, and pathophysiology of nonalcoholic fatty liver disease (NAFLD) in women with polycystic ovary syndrome (PCOS)[J]. Biomedicines, 2022, 10(1): 131.
Kelley CE, Brown AJ, Diehl AM, et al. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome[J]. World J Gastroenterol, 2014, 20(39): 14172-14184.
Sarkar M, Terrault N, Chan W, et al. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis[J]. Liver Int, 2020, 40(2): 355-359.
Xia MF, Lin HD, Yan HM, et al. The association of liver fat content and serum alanine aminotransferase with bone mineral density in middle-aged and elderly Chinese men and postmenopausal women[J]. J Transl Med, 2016, 14: 11.
Pan XY, Han YJ, Zou TT, et al. Sarcopenia contributes to the progression of nonalcoholic fatty liver disease- related fibrosis: a meta-analysis[J]. Dig Dis, 2018, 36(6): 427-436.
Yang YJ, Kim DJ. An overview of the molecular mechanisms contributing to musculoskeletal disorders in chronic liver disease: osteoporosis, sarcopenia, and osteoporotic sarcopenia[J]. Int J Mol Sci, 2021, 22(5): 2604.
Chung GE, Kim D, Kwak MS, et al. Longitudinal change in thyroid-stimulating hormone and risk of nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2021, 19(4): 848-849.e1.
Chen YL, Tian S, Wu J, et al. Impact of thyroid function on the prevalence and mortality of metabolic dysfunction-associated fatty liver disease[J]. J Clin Endocrinol Metab, 2023, 108(7): e434-e443.
Lonardo A, Ballestri S, Mantovani A, et al. Pathogenesis of hypothyroidism-induced NAFLD: evidence for a distinct disease entity?[J]. Dig Liver Dis, 2019, 51(4): 462-470.
Mesarwi OA, Loomba R, Malhotra A. Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease[J]. Am J Respir Crit Care Med, 2019, 199(7): 830-841.
Almendros I, Basoglu ÖK, Conde SV, et al. Metabolic dysfunction in OSA: is there something new under the Sun?[J]. J Sleep Res, 2022, 31(1): e13418.
Krolow GK, Garcia E, Schoor F, et al. Obstructive sleep apnea and severity of nonalcoholic fatty liver disease[J]. Eur J Gastroenterol Hepatol, 2021, 33(8): 1104-1109.
Roberts KK, Cochet AE, Lamb PB, et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic[J]. Aliment Pharmacol Ther, 2015, 41(3): 293-300.
Ruan ZJ, Lu T, Chen YX, et al. Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults[J]. JAMA Dermatol, 2022, 158(7): 745-753.
Candia R, Ruiz A, Torres-Robles R, et al. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis[J]. J Eur Acad Dermatol Venereol, 2015, 29(4): 656-662.
Heitmann J, Frings VG, Geier A, et al. Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network?[J]. J Dtsch Dermatol Ges, 2021, 19(4): 517-528.
Wu WW, Li XW, Cui LH. The value of changes in diagnostic criteria for fatty liver in stratified management of cardiovascular risk[J]. Med J Chin PLA, 2021, 46(5): 486-491.
吴婉雯, 李晓伟, 崔立红. 脂肪肝诊断标准的变更对心血管疾病风险分层管理的价值分析[J]. 解放军医学杂志, 2021, 46(5): 486-491.
Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209.
Lee H, Lee YH, Kim SU, et al. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study[J]. Clin Gastroenterol Hepatol, 2021, 19(10): 2138-2147.e10.
Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD[J]. Liver Int, 2020, 40(12): 3018-3030.
Gofton C, Upendran Y, Zheng MH, et al. MAFLD: how is it different from NAFLD?[J]. Clin Mol Hepatol, 2023, 29(Suppl): S17-S31.
Fu YM, Wang CY, Li ZB, et al. Grading diagnostic efficiency of controlled attenuation parameter on hepatic steatosis of patients with nonalcoholic fatty liver disease[J]. Med J Chin PLA, 2022, 47(6): 593-598.
付懿铭, 王春艳, 李忠斌, 等. 受控衰减参数对非酒精性脂肪性肝病患者肝脂肪变性分级的诊断价值[J]. 解放军医学杂志, 2022, 47(6): 593-598.
Huang Q, Zou X, Wen X, et al. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality? -results from NHANES Ⅲ[J]. Front Med(Lausanne), 2021, 8: 693507.
Younossi ZM, Paik JM, Al Shabeeb R, et al. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?[J]. Hepatology, 2022, 76(5): 1423-1437.
Moon JH, Kim W, Koo BK, et al. Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease[J]. Gut Liver, 2022, 16(3): 433-442.
Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts[J]. N Engl J Med, 2018, 378(25): e34.
Wiese M, Bashmakov Y, Chalyk N, et al. Prebiotic effect of lycopene and dark chocolate on gut microbiome with systemic changes in liver metabolism, skeletal muscles and skin in moderately obese persons[J]. Biomed Res Int, 2019, 2019: 4625279.
Rong L, Zou JY, Ran W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)[J]. Front Endocrinol (Lausanne), 2022, 13: 1087260.
Mantovani A, Petracca G, Beatrice G, et al. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials[J]. Metabolites, 2021, 11(2): 73.
Patel Chavez C, Cusi K, Kadiyala S. The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD[J]. J Clin Endocrinol Metab, 2022, 107(1): 29-38.
Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes[J]. Diabetes Care, 2020, 43(6): 1352-1355.
Ribeiro Dos Santos L, Baer Filho R. Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients[J]. Metabol Open, 2020, 5: 100028.
Taheri H, Malek M, Ismail-Beigi F, et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial[J]. Adv Ther, 2020, 37(11): 4697-4708.
Itani T, Ishihara T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study[J]. Obes Sci Pract, 2018, 4(5): 477-482.
Takahashi H, Kessoku T, Kawanaka M, et al. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD[J]. Hepatol Commun, 2022, 6(1): 120-132.
Gu YP, Sun L, Zhang W, et al. Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: a GRADE-assessed systematic review and network meta-analysis of randomized controlled trials[J]. Front Pharmacol, 2023, 14: 1102792.
Mantovani A, Byrne CD, Scorletti E, et al. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials[J]. Diabetes Metab, 2020, 46(6): 427-441.
Kaplan DE, Serper M, John BV, et al. Effects of metformin exposure on survival in a large national cohort of patients with diabetes and cirrhosis[J]. Clin Gastroenterol Hepatol, 2021, 19(10): 2148-2160.e14.
Nassir F. NAFLD: mechanisms, treatments, and biomarkers[J]. Biomolecules, 2022, 12(6): 824.
Cho Y, Rhee H, Kim YE, et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)[J]. BMC Med, 2022, 20(1): 93.
Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 362(18): 1675-1685.
Vilar-Gomez E, Vuppalanchi R, Gawrieh S, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis[J]. Hepatology, 2020, 71(2): 495-509.
Cusi K, Isaacs S, Barb D, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American association for the study of liver diseases (AASLD)[J]. Endocr Pract, 2022, 28(5): 528-562.
Boeckmans J, Natale A, Rombaut M, et al. Anti-NASH drug development hitches a lift on PPAR agonism[J]. Cells, 2019, 9(1): 37.
Prikhodko VA, Bezborodkina NN, Okovityi SV. Pharmacotherapy for non-alcoholic fatty liver disease: emerging targets and drug candidates[J]. Biomedicines, 2022, 10(2): 274.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357.
Lee YH, Kim JH, Kim SR, et al. Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness[J]. J Korean Med Sci, 2017, 32(1): 60-69.
Zarei M, Barroso E, Palomer X, et al. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease[J]. Mol Metab, 2018, 8: 117-131.
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385(9972): 956-965.
Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial[J]. Hepatology, 2021, 74(4): 1809-1824.
Francque SM, Bedossa P, Ratziu V, et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH[J]. N Engl J Med, 2021, 385(17): 1547-1558.
Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2019, 394(10215): 2184-2196.
Baruch A, Wong C, Chinn LW, et al. Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans[J]. Proc Natl Acad Sci U S A, 2020, 117(46): 28992-29000.
Harrison SA, Abdelmalek MF, Neff G, et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(7): 603-616.
Harrison SA, Ruane PJ, Freilich BL, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial[J]. Nat Med, 2021, 27(7): 1262-1271.
Pan Q, Lin SS, Li Y, et al. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis[J]. EBioMedicine, 2021, 63: 103202.
Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2019, 394(10213): 2012-2024.
Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(5): 279-297.
Maestri M, Santopaolo F, Pompili M, et al. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: effects of current treatments and future strategies[J]. Front Nutr, 2023, 10: 1110536.
Abou Assi R, Abdulbaqi IM, Siok Yee C. The evaluation of drug delivery nanocarrier development and pharmacological briefing for metabolic-associated fatty liver disease (MAFLD): an update[J]. Pharmaceuticals (Basel), 2021, 14(3): 215.
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies